Charles Hayes, Victoria Sigeti, David Brooks, Emily Rich, Maria Ledeneva, Christopher Yarrow
January 24, 2026
Freshfields advises CVC Fund VIII on investment in Spectrum Medical Group

1 min
AI-made summary
- Freshfields Bruckhaus Deringer has advised CVC Capital Partners Fund VIII on its definitive investment and partnership agreement with Spectrum Medical Group Limited, valuing Spectrum Medical at up to £1 billion
- Spectrum Medical has experienced rapid growth by introducing new technologies in the cardiac bypass and ICU sectors
- CVC’s investment aims to support Spectrum Medical’s growth strategy
- The Freshfields team is led by partners Charles Hayes, Victoria Sigeti, and David Brooks.
Freshfields Bruckhaus Deringer (‘Freshfields’) has advised CVC Capital Partners Fund VIII (‘CVC’) on its definitive investment and partnership agreement to support the continued growth of Spectrum Medical Group Limited (‘Spectrum Medical’), valuing Spectrum Medical at up to £1bn. Spectrum Medical has grown rapidly over the past few years by bringing new and pioneering technologies to the cardiac bypass and ICU space. The company’s vision is driven by clinical excellence and outcomes, and is committed to partnering with the world’s leading clinicians in the implementation of clinical best practice. CVC’s investment will support Spectrum Medical’s ambitious growth strategy to continue transforming the cardiac space and improving patient outcomes. The Freshfields’ team is being led by partners Charles Hayes, Victoria Sigeti, and David Brooks, and senior associates Emily Rich, Maria Ledeneva, and Christopher Yarrow. Further info on the agreement can be found here.
Article Author
Charles Hayes, Victoria Sigeti, David Brooks, Emily Rich, Maria Ledeneva, Christopher Yarrow
The Sponsor
